Healthtech Investors & VC Firms in North America

2667 firms in this list, with a median first check of $500K. 649 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
AN AN Venture Partners KHANJHTF22 people · Follows rounds	88🔒	Tokyo	JP	Seed–Growth	—	+ Add to CRM
AL Alpana Ventures CCNCPHHL9 people	88🔒	Geneva	CH	Seed–Series A	—	+ Add to CRM
DE DeVC AKKBRMRA6 people · Follows rounds	88🔒	Bengaluru	IN	Pre-Seed–Seed	$50K – $500K	+ Add to CRM
PR Privilège Ventures AMJRHKMJ12 people · Follows rounds	88🔒	Lugano	CH	Pre-Seed–Series A	$100K – $1M	+ Add to CRM
BU Builders + Backers DHEBKHMC17 people	88🔒	—		Pre-Seed	—	+ Add to CRM
LA Lauxera Capital Partners ASPMSLEF17 people · Leads rounds	88🔒	Paris	FR	Growth	$22M – $110M	+ Add to CRM
AU Auriga Partners JCCLGRMC16 people	88🔒	Paris	FR	Seed–Growth	$540K – $5.4M	+ Add to CRM
BR Brookstreet Equity Partners EGODCSLS22 people · Leads rounds	88🔒	London	GB	Series A–Late Stage	—	+ Add to CRM
EA Eaton Square BADBMUAM25 people	88🔒	London	GB	Series A–Growth	—	+ Add to CRM
AD ADVANTAGE ABCCJPJW20 people	88🔒	Jerusalem	IL	Pre-Seed–Series A	—	+ Add to CRM
NO Nordic Capital CHHJJSKM11 people · Leads rounds	88🔒	Copenhagen	DK	Growth–Late Stage	—	+ Add to CRM
QU Quan Capital SDMWSXYY17 people	88🔒	Shanghai	CN	Seed–Growth	—	+ Add to CRM
FO Fountain Healthcare Partners AKMREPJL8 people · Leads rounds	88🔒	Dublin	IE	Seed–Series A	$10.8M – $16.2M	+ Add to CRM
BC BC Partners LCMCMCAB23 people	88🔒	London	GB	Growth–Late Stage	—	+ Add to CRM
MD MDI Ventures RRSLDWKK11 people · Leads rounds	88🔒	Jakarta	ID	Pre-Seed–Growth	—	+ Add to CRM
XG XGEN Venture DSFDPFSV21 people	88🔒	Milan	IT	Pre-Seed–Series A	—	+ Add to CRM
BI Bioqube Ventures DDNVDRJV17 people	88🔒	Brussels	BE	Pre-Seed–Series B	$108K – $6.5M	+ Add to CRM
KE Keensight Capital AKSDYYCG4 people · Leads rounds	88🔒	Paris	FR	Growth–Late Stage	$10M – $800M	+ Add to CRM
PR Prime Partners JCLZRLRM4 people	88🔒	Tokyo	JP	Pre-Seed–Growth	—	+ Add to CRM
CL Cloud Health Euroventures ECMCAPAC21 people · Follows rounds	88🔒	—	RS	Pre-Seed–Series A	$100K – $1M	+ Add to CRM
BO Boehringer Ingelheim Venture Fund SEMHBHMB16 people	88🔒	Ingelheim am Rhein	DE	Seed–Growth	$16.2M	+ Add to CRM
PR Project Ventures KWRPRHCV7 people	88🔒	Berlin	DE	Pre-Seed–Seed	—	+ Add to CRM
HB HBM Partners FDCLDDSS6 people	88🔒	Zug	CH	Seed–Late Stage	$5M – $50M	+ Add to CRM
SE Senovo ABFMMGMG8 people	88🔒	Munich	DE	Seed–Series A	$1.1M – $5.4M	+ Add to CRM

AN Venture Partners

TokyoSeed–Growth

KHANJHTF22 people

Alpana Ventures

GenevaSeed–Series A

CCNCPHHL9 people

DeVC

BengaluruPre-Seed–Seed$50K – $500K

AKKBRMRA6 people

Privilège Ventures

LuganoPre-Seed–Series A$100K – $1M

AMJRHKMJ12 people

Builders + Backers

Pre-Seed

DHEBKHMC17 people

Lauxera Capital Partners

ParisGrowth$22M – $110M

ASPMSLEF17 people

Auriga Partners

ParisSeed–Growth$540K – $5.4M

JCCLGRMC16 people

Brookstreet Equity Partners

LondonSeries A–Late Stage

EGODCSLS22 people

Eaton Square

LondonSeries A–Growth

BADBMUAM25 people

ADVANTAGE

JerusalemPre-Seed–Series A

ABCCJPJW20 people

Nordic Capital

CopenhagenGrowth–Late Stage

CHHJJSKM11 people

Quan Capital

ShanghaiSeed–Growth

SDMWSXYY17 people

Fountain Healthcare Partners

DublinSeed–Series A$10.8M – $16.2M

AKMREPJL8 people

BC Partners

LondonGrowth–Late Stage

LCMCMCAB23 people

MDI Ventures

JakartaPre-Seed–Growth

RRSLDWKK11 people

XGEN Venture

MilanPre-Seed–Series A

DSFDPFSV21 people

Bioqube Ventures

BrusselsPre-Seed–Series B$108K – $6.5M

DDNVDRJV17 people

Keensight Capital

ParisGrowth–Late Stage$10M – $800M

AKSDYYCG4 people

Prime Partners

TokyoPre-Seed–Growth

JCLZRLRM4 people

Cloud Health Euroventures

Pre-Seed–Series A$100K – $1M

ECMCAPAC21 people

Boehringer Ingelheim Venture Fund

Ingelheim am RheinSeed–Growth$16.2M

SEMHBHMB16 people

Project Ventures

BerlinPre-Seed–Seed

KWRPRHCV7 people

HBM Partners

ZugSeed–Late Stage$5M – $50M

FDCLDDSS6 people

Senovo

MunichSeed–Series A$1.1M – $5.4M

ABFMMGMG8 people

Data sourced from public filings and firms' own websites — see our methodology.